Opportunities
Search

The Office of Science (SC) of the Department of Energy (DOE) hereby announces its continuing interest in receiving applications for support of work in the following program areas: Advanced Scientific Computing Research, Basic Energy Sciences, Biological and Environmental Research, Fusion Energy Sciences, High Energy Physics, Nuclear Physics, and Isotope R&D and Production. On September 3, 1992, DOE published in the Federal Register the Office of Energy Research Financial Assistance Program (now called the Office of Science Financial Assistance Program), 10 CFR 605, as a Final Rule, which contained a solicitation for this program. Information about submission of applications, eligibility, limitations, evaluation and selection processes and other policies and procedures are specified in 10 CFR 605.   This NOFO is our annual open solicitation that covers all research areas in SC and is open throughout the Fiscal Year. Any research within SC’s Congressionally authorized mission may be proposed under this NOFO.   This NOFO will remain open until September 30, 2026, 11:59 PM Eastern Time, or until it is succeeded by another issuance, whichever occurs first. This NOFO succeeds DE-FOA-0003432, which was published September 30, 2024.

The Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office (BTO) is soliciting proposals that leverage biological properties and processes to revolutionize our ability to protect the nation’s warfighters. Specifically excluded is research that primarily results in evolutionary improvements to the existing state of practice.

The U.S. Fish and Wildlife Service (Service) Partners for Fish and Wildlife (PFW) Program helps private landowners restore and protect habitats for fish and wildlife. It offers both technical assistance and financial support, mainly through cooperative agreements.The PFW Program has approximately 220 staff working in all 50 states and territories. They work together with project partners and stakeholders to find key areas for conservation and set habitat goals. These focus areas guide the program on where to direct resources for conserving important habitats for federal trust species. The Program also has strategic plans that help determine which projects receive funding.Since it began in 1987, the PFW Program has successfully assisted many landowners. When choosing projects, the Program aims to support specific priorities set by the Secretary of the Interior and identified in regional strategic habitat conservation plans. All projects will promote the goals of the Program, the Department of the Interior, and the U.S. Fish and Wildlife Service. These goals focus on using sound biological principles and voluntary partnerships to accomplish the mission of the Service to work with others to conserve, protect and enhance fish, wildlife, plants and their habitats for the continuing benefit of the American people.Applicants seeking technical or financial assistance from the PFW Program are required to consult with a local Program office BEFORE developing or submitting an application by visiting our website.

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Idea Award (TIA) supports new, innovative, high-risk, high-gain ideas aimed at amyotrophic lateral sclerosis (ALS) drug or therapy discovery. The studies supported by this award mechanism are expected to be hypothesis-driven and generate preliminary data for future avenues of therapeutic investigation.Distinctive Features: Potential impact and innovation are important features of the TIA. Applications may demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis. While the inclusion of preliminary data is not prohibited, the strength of the application should rely on the approach.

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Breakthrough Award mechanism supports promising research with high potential to lead to or make breakthroughs in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. Applications must address the challenge in a way that can lead to a breakthrough and have major impact. The FY26 Breakthrough Award mechanism contains four different funding levels designed to support major (but not all) stages of research that will lead to clinical application. Each level specifies a distinct research scope. This program announcement discusses the Breakthrough Award Level 3.Distinctive Features:·        For this funding mechanism, small-scale clinical trials are allowed but not required. Applications proposing projects with a clinical trial should be submitted under the Clinical Trial option.·        The research team must include two or more breast cancer consumer advocates.·        This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. For the Partnering PI Option (PPIO), only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Initiating and Partnering PI) applications by the deadline may result in administrative withdrawal.

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA) supports research ranging from preclinical validation of therapeutic leads through U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product-driven. Applicants with limited amyotrophic lateral sclerosis (ALS) experience are strongly encouraged to include collaborators with substantial experience in the relevant ALS model systems, endpoints and pathophysiology.Applications supported by this award must begin with lead compounds in hand and must already demonstrate proof-of-concept efficacy data in at least one appropriate preclinical model system of ALS, including whole-animal and cellular model systems.Distinctive Features: Mechanism-specific, predictive/cohort-selective, target engagement and pharmacodynamic biomarker development, in parallel to the main therapeutic effort, is a critical component of the FY26 ALSRP Therapeutic Development Award. If appropriate mechanism-specific biomarkers are already available or currently in development, how the existing biomarkers will improve trial design, patient selection, and efficiency or interpretation of the proposed ALS therapeutic approach must be apparent in the application. Development of biomarkers for the purposes of diagnosis, prognosis, or measurement of general disease progression without consideration of the therapeutic development process will not be supported.Therapeutic candidates which have...

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Transformative Breast Cancer Consortium Award supports collaborations and ideas that will transform the lives of individuals with, and/or at risk for, breast cancer and will significantly accelerate progress toward ending breast cancer. Applications must propose a synergistic, highly integrated, multidisciplinary and multi-institutional consortium of leading scientists, clinicians and breast cancer consumer advocates that will address a major problem in a way that a single investigator or group could not accomplish. The consortium’s collaborative efforts must make a transformative impact in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. If the application addresses a different fundamental issue, the application must couple it with at least one of the overarching challenges.Distinctive Features: This funding mechanism allows for up to five Principal Investigators (PIs) which includes the Consortium Director and three or four Project Team PIs. Applications must include at least one breast cancer consumer advocate per project team. Only the Consortium Director will submit a pre-application, but all PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Consortium Director and Project Team PIs) applications by the full application deadline may result in administrative withdrawal.

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in amyotrophic lateral sclerosis (ALS). Projects can be relevant to a specific therapy, a class of therapeutics, or to a specific ALS subtype (such as a particular genetic mutation) and do not have to broadly apply to all patients.Distinctive Features: To meet the intent of the funding opportunity, applications may address clinical biomarkers and/or clinical outcomes. This may include the identification, development, and/or validation of promising biomarkers for ALS, which may include, but are not limited to susceptibility/risk, diagnostic, monitoring/disease progression, prognostic, predictive, response, or safety biomarkers. Clinical Outcomes projects may focus on the identification, development, and/or validation of clinician-, observer-, or patient-reported, and/or performance outcome measures for ALS. Projects may include the optimization of current outcome measures already in use.Applications may utilize digital health measures, including wearable devices, smart-phone sensors, video or voice recordings, imaging studies, or other devices which record disease-relevant physiological data and/or outcomes.Community Collaboration is an important element of the FY26 ALSRP COBA. Applicants will be expected to articulate how the proposed research question or study design was informed by theALS lived experience community.

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Breakthrough Award mechanism supports promising research with high potential to lead to or make breakthroughs in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. Applications must address the challenge in a way that can lead to a breakthrough and have major impact. The FY26 Breakthrough Award mechanism contains four different funding levels designed to support major (but not all) stages of research that will lead to clinical application. Each level specifies a distinct research scope. This program announcement discusses the Breakthrough Award Level 4.Distinctive Features:·        Clinical trials are required.·        The research team must include two or more breast cancer consumer advocates.·        This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. For the Partnering PI Option (PPIO), only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Initiating and Partnering PI) applications by the deadline may result in administrative withdrawal.

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Pilot Clinical Trial Award (PCTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of amyotrophic lateral sclerosis (ALS). Projects may range from phase 1 to small-scale phase 2 trials.Applications must address one of the following focus areas:·        Biomarker-Driven Interventions: Disease-modifying interventions, with mechanism-specific biomarkers to predict which clinical trial participants are likely to respond, demonstrate target engagement, and effects on the intended biological pathway.·        Clinical Care: Improving aspects of clinical care and symptom management for ALS.Distinctive Features: Funding from this award mechanism must support a clinical trial. The clinical trial should begin no later than 12 months after the award date or 18 months for U.S. Food and Drug Administration (FDA)-regulated studies.Projects proposing a therapeutic intervention (drug, biologic, and/or device) must incorporate biomarkers specific to the intervention into the trial design.All pre-applications and applications are required to incorporate community collaboration, as described in Section 3.2.2, to optimize research impact.Applications must include a detailed Regulatory Strategy plan that outlines the approach for obtaining regulatory approvals, if required, specifically for the funded portion of the study. In addition, applications must provide a separate Transition Plan that describes how the outcomes of t...

Water Resource Research Act (WRRA) coordination award to support efforts toward water resources research.

The U.S. Fish and Wildlife Service (Service) Coastal Program provides technical and financial assistance to partners to support projects that protect and restore fish and wildlife habitats on public and private lands in priority coastal ecosystems. This support is provided through cooperative agreements with conservation partners and landowners, including state and Tribal agencies. Coastal Program staff work with partners, stakeholders, and other Service programs in important areas for conservation. They implement regional strategic plans that identify priority species and habitats for conservation in these focus areas.Applicants seeking technical or financial assistance from the Coastal Program are required to contact a local Program office BEFORE developing or submitting an application. You can find this information in the current strategic plan at this link or by contacting your local Coastal Program office at https://www.fws.gov/program/coastal/contact-us.Projects are developed collaboratively by partners and Service field staff. All Coastal Program projects must align with the missions of the U.S. Department of the Interior, the U.S. Fish and Wildlife Service, and the Coastal Program. They are also based on sound biological principles and the best available science.

This is a NOFO for a Single Source competition that will invite application(s) from eligible organization(s) to apply. Please see Eligibility Section for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered for funding.The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is announcing its intent to issue a single source cooperative agreement award to Beckman Research Institute/City of Hope for the currently funded Integrated Islet Distribution Program (IIDP) to renew the program and maintain support for its continuing mission to provide the scientific community with important islet resources for diabetes research. The IIDP facilitates the distribution of human islets to biomedical researchers by establishing partnerships with qualified islet isolation facilities to prepare and distribute human islets. Human islets remain an essential resource for diabetes research to advance our understanding of human islet cell biology, and to promote the development of new therapies for the prevention and treatment of diabetes.This NOFO is associated with the Special Diabetes Program (https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/type-1-diabetes-special-statutory-funding-program/about-special-diabetes-program) which funds research on the prevention, treatment, and cure of type 1 diabetes and its complications, including unique, innovative, and collaborative research consortia and clinical trials networks.

The purpose of this notice of funding opportunity (NOFO) is to establish a Center that trains researchers in formal product development for new substance use disorder (SUD) pharmacotherapeutics and to advance the best concepts through initial experiments via technical and financial support.

This Notice of Funding Opportunity (NOFO) invites a single cooperative agreement application for the Resource Center for the Cardiovascular Repository for Type 1 Diabetes (CaRe-T1D). The purpose of CaRe-T1D is to support innovative, discovery and mechanistic research through the study of human cardiovascular (CV) tissue. This research seeks to better understand cardiovascular disease (CVD) in type 1 diabetes, highlight differences compared to type 2 diabetes, and ultimately guide the development of therapies to treat this major cause of morbidity and mortality for individuals with type 1 diabetes. To achieve these goals, the Resource Center will expand the CaRe-T1D biorepository of human CV tissue, further develop the data commons for data sharing and for artificial intelligence (AI) tools, coordinate the research activities of the investigative teams in the CaRe-T1D consortium, and make CaRe-T1D resources accessible to the broader research community. This NOFO is associated with the Special Diabetes Program (https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/type-1-diabetes-special-statutory-funding-program/about-special-diabetes-program) which funds research on the prevention, treatment, and cure of type 1 diabetes and its complications, including unique, innovative, and collaborative research consortia and clinical trials networks.This is a Notice of Funding Opportunity (NOFO) for a Single Source that will invite application(s) from eligible organization(s) to apply. Please see Section III. Eligibility for additional information. In accordance with NIH standar...

Summary: The fiscal year 2026 (FY26) Rare Cancers Research Program (RCRP) Concept Award (CA) supports highly innovative, untested, potentially groundbreaking novel concepts in rare cancers. Applications must describe how the new idea will be innovative and present as a novel course of investigation in the field of rare cancers.Distinctive Features:Preliminary data are not required.Due to the blinded nature of the review process, identifying or making references to the Principal Investigator (PI), collaborator(s), or their organization(s) in the proposal Project Narrative, Supporting Documentations, Impact Statement, Justification Statement, and Statement of Work (SOW) is prohibited and will result in administrative rejection of the application.

Expected Outcome:Project results are expected to contribute to all of the following expected outcomes:AI-based demonstrators for Earth Intelligence tools integrating observations and socio-economic data, for evidence-based decision making. Whereby Earth Intelligence refers to data-driven decision support tools with relevant research-based assessments, data, and options;support to national, EU and international environmental policy making or implementation (e.g. European Climate Law, Preparedness Union Strategy, Nature Restoration Regulation, Paris Agreement, or Sustainable Development Goals). Scope:Proposals should develop and demonstrate downstream applications for a range of use cases (e.g. weather-, climate-related risks, environmental hazards, or biodiversity reporting) using broadly and intensively Earth Observation and relevant datasets for supporting sustainability and competitive...

Support European Food Bank Federation’s capacity building - 2026-2027

Expected Outcome:Deliverables:Initiatives implemented for the target audience to collect knowledge on learning needs in the area of AI uptake in health.Training programmes in the area of advanced digital skills for AI uptake in health, designed jointly by higher education institutions, VET providers, research organisations, businesses and other stakeholders in digital health, in collaboration with the network of AI-powered advanced screening centres.Training catalogue with detailed course planning and timetable, regularly updated.Final analysis of the completed training and the achievement level reached in improved skills.A landing page integrated into the Digital Skills and Jobs Platform, showcasing existing and forthcoming education and training initiatives and promoting training offers to the relevant audience. Objective:The academic offer in the area of advanced digital technologies...

Expected Impact:The objective is to deliver three to four projects that demonstrate the streamlining of regulatory reporting through automated and trusted sharing of compliance data. Each project will address the governance, technical, legal, and processing aspects of the solution. Objective:Specific Objective 2 of the Digital Europe Programme aims to reinforce the EU’s core Artificial Intelligence (AI) capacities as a crucial driver for the digital transformation of the public and private sectors. The vision is to make Europe an AI continent, thriving on the development, integration and adoption of AI. As one of the financial instruments of the upcoming Apply AI Strategy, SO2 will support the development of world class AI models in the EU and foster the integration of AI technologies into EU’s most strategic sectors, including healthcare, energy and research. It will stimulate new indus...

Expected Outcome:1. Comprehensive support to EDICs, the Commission and Member States by:   the provision of legal and operational advice to established EDICs, including on the compliance with the DDPP Decision, other EU legislation and where applicable national legislation; and maintaining a repository of thereof; support the Commission and Member States on the EDICs in preparation and in identifying and mobilising new EDIC initiatives, pursuing outreach activities and reporting progress in the State of the Digital Decade Report;creating and maintaining of consolidated data and information repository on EDICs, including best practices and data promoting EDIC results (quantified where possible), and reporting; accessible to relevant stakeholders;  liaising and coordination between EDICs as well as between EDICs and other MCP implementation mechanisms and other relevant stakeholders,  base...

Expected Outcome:Deliverable:Connected National Coalitions for Digital Skills and Jobs to the Core Platform. Objective:The Digital Skills and Jobs Platform provides a single point of information related to digital skills in Europe. At EU level, the Platform gathers all relevant information and funding opportunities for stakeholders to benefit from. At national level, it connects to National Coalition websites, establishing a mutually enriching exchange with relevant content and data on digital skills and jobs. In 2024, 22 national websites are connected to the Platform. Additional Member States websites will be connected by the ongoing project on National Coalitions for Digital Skills and Jobs[1] by 2026. The Platform also hosts the Cyber Security Skills Academy and will host other relevant sectoral academies and initiatives. The objective of this topic is to consolidate and uphold the o...

Expected Outcome:At a general level, the project should achieve a strong, visible and recognised impact in scaling, facilitating and accelerating research and analytical efforts focussing on the information environment and information integrity. The main outcomes of the awarded project will be: The technical solutions created or supported The insights generated from supported research and monitoring projects The proof of concept and lessons learnt for the support of shared infrastructures to support research on the information environment Project applications will formulate their own deliverables in accordance with their needs analyses and proposed means to address them. At the minimum, deliverables should include: A suite or network of solutions capable of addressing Specific Objectives 1 and 2 (c.f. section 2 ‘Scope – Specific Objectives 1 and 2’) A methodology and dissemination plan f...

Expected Outcome:Deliverables:​​​​​​Three open calls for pilots (at least one call per year) launched and managed providing financial support to third parties to at least 20 EdTech start-ups/SMEs from across Member States and eligible countries. A minimum of 60% of the total budget should be spent on Financial Support for Third Parties (FSTP) and the maximum amount per third party can amount up to 150.000 EUR to allow short pilots testing in real education or training environments;Developed and implemented a yearly 12-months incubation and acceleration programme providing a mix of mentoring, networking services, consultancy, training and/or business and access-to-market support to the selected companies;Short pilots implemented in real education and training environments to gather impact assessment data of the selected solutions. Human-centric design methods involving users and strong li...

Expected Impact:naExpected Outcome:Outcomes and deliverablesOne or more proofs-of-concept of replicable, scalable cloud-based AI/GenAI systems for analysis of medical imaging data in a healthcare setting, with demonstration of the role of the clinicians in validating AI/GenAI findings and reports showcasing seamless integration of the system into clinical workflows.Evidence-based analysis of (cost-)efficiency of the piloted solutions for healthcare systems for regulatory and HTA purposes.Two or more events or workshops organised per year and per project for the European network of AI-powered advanced screening centres. The agenda should include lessons learned from the project activities, as well as other items relevant to the network. Participant satisfaction rates should be measured for the events and workshops.Medical centres in the consortium joined the European network of AI-powered...